Erlotinib, the first FDA-approved EGFR-TKI for treating EGFR-mutated non-small cell lung cancer and pancreatic cancer, shows efficacy in some HNSCC patients [28,43]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.